In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

Ex Input:
To combat the threat of many emerging infectious diseases, DNA immunization offers a unique and powerful approach to the production of high-quality monoclonal antibodies (mAbs) against various pathogens. Compared with traditional protein-based immunization approaches, DNA immunization is efficient for testing novel immunogen designs, does not require the production or purification of proteins from a pathogen or the use of recombinant protein technology and is effective at generating mAbs against conformation-sensitive targets. Although significant progress in the use of DNA immunization to generate mAbs has been made over the last two decades, the literature does not contain an updated summary of this experience. The current review provides a comprehensive analysis of the literature, including our own work, describing the use of DNA immunization to produce highly functional mAbs, in particular, those against emerging infectious diseases. Critical factors such as immunogen design, delivery approach, immunization schedule, use of immune modulators and the role of final boost immunization are discussed in detail.

Ex Output:
DNA immunization as a technology platform for monoclonal antibody induction


Ex Input:
Streptococcus pneumoniae is the main cause of diseases such as meningitis, pneumoniae and sepsis, especially in children and old people. Due to costly antibiotic treatment, and increasing resistance of pneumococcus, developing high-efficient protective vaccine against this pathogen is an urgent need. Although the pneumoniae polysaccharide vaccine (PPV) and pneumonia conjugate vaccines (PCV) are the efficient pneumococcal vaccine in children and adult groups, but the serotype replacement of S. pneumoniae strains causes the reduction in efficacy of such vaccines. For overcoming the aforesaid drawbacks epitope-based vaccines are introduced as the relevant alternative. In our previous research, the epitope vaccine was designed based on immunodominant epitopes from PspA, CbpA antigens as cellular stimulants and PhtD, PiuA as humoral stimulants. Because the low immunogenicity is the main disadvantage of epitope vaccine, in the current study, we applied coiled-coil selfassembled structures for developing our vaccine. Recently, self-assembled peptide nanoparticles (SAPNs) have gained much attention in the field of vaccine development due to their multivalency, self-adjuvanticity, biocompatibility, and size similarity to pathogen. In this regard, the final designed vaccine is comprised of cytotoxic T lymphocytes (CTL) epitopes from PspA and CbpA, helper T lymphocytes (HTL) epitopes from PhtD and PiuA, the pentamer and trimmer oligomeric domains form 5-stranded and 3-stranded coiled-coils as self-assembled scaffold, Diphtheria toxoids (DTD) as a universal T-helper, which fused to each other with appropriate linkers. The four different arrangements based on the order of above-mentioned compartments were constructed, and each of them were modeled, and validated to find the 3D structure. The structural, physicochemical, and immunoinformatics analyses of final vaccine construct represented that our vaccine could stimulate potent immune response against S. pneumoniae; however, the potency of that should be approved via various in vivo and in vitro immunological tests.

Ex Output:
Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy


Ex Input:
A mong the infl ammatory processes triggering COPD exacerbations, respiratory tract viral infections are prime suspects. Although fi rst localized in the upper-respiratory tract (URT), these infections could trigger a cascade of infl ammatory events 1,2 that lead to clinically signifi cant exacerbations. Current guidelines recommend the administration of antibiotics based mainly on clinical criteria, 1 leading inevitably to an overuse of antibiotics, which is estimated to occur in approximately 55% of all acute exacerbations of COPD (AECOPD). 3 The participation of viral infections in AECOPD has been confi rmed in many studies. 4-7 The most recent reports using polymerase chain reaction (PCR)-based methods led to a positive detection of viral nucleic acids in 30% to 60% of AECOPD cases. 5,8-12 However, the role of recently identifi ed viruses, such as coronavirus NL63 and HKU1 and human bocavirus as well as the new human rhinoviruses C, which are reported as the most frequent ones circulating in the community, 13, 14 has not yet been fully established. Biomarkers such as procalcitonin (PCT), when elevated, have been proposed as surrogate markers of bacterial disease and, when within normal values, often are considered in clinical practice as the signature of a viral infection. Although PCT has been studied Background: Respiratory viruses frequently are recovered in the upper-respiratory tract during acute exacerbations of COPD (AECOPD), but their role as contributing pathogens remains unclear. The usefulness of procalcitonin and C-reactive protein as indicators of the presence or absence of viral infection in this setting also needs to be evaluated. Methods: The study was of a prospective cohort of patients with COPD admitted to the ED for AECOPD. Reverse transcriptase-polymerase chain reaction (RT-PCR) for 14 respiratory viruses was performed on nasopharyngeal swabs collected at admission and after recovery in stable condition. Conclusions: Prevalence of upper-respiratory viral infection, as detected from nasopharyngeal swab by RT-PCR, is high in AECOPD and low after clinical recovery, suggesting that AECOPD frequently are triggered by viral infections initiated in the upper-respiratory tract. In our study, serum procalcitonin and C-reactive protein did not discriminate virus-associated exacerbations from others. Trial registration: clinicaltrials.gov; Identifi er: NCT00448604. Abbreviations: AECOPD 5 acute exacerbations of COPD; CRP 5 C-reactive protein; OR 5 odds ratio; PCR 5 polymerase chain reaction; PCT 5 procalcitonin; PEF 5 peak expiratory fl ow; RSV 5 respiratory syncytial virus; RT-PCR 5 reverse transcriptase-polymerase chain reaction; URT 5 upper-respiratory tract

Ex Output:

Upper-Respiratory Viral Infection, Biomarkers, and COPD Exacerbations